A neoadjuvant strategy for the management of nonmetastatic pancreatic cancer

Cancer Journal (United States)

Volumn 18, Issue 6, 2012, Pages 602-608

  Goff, Stephanie L ^a   Chabot, John A ^a  

^a College of Physicians and Surgeons ^*  (United States)

Author keywords

borderline resectable pancreatic cancer; locally advanced pancreatic cancer; neoadjuvant therapy; Pancreatic cancer; potentially resectable pancreatic cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE PLUS OXALIPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; GEMCITABINE; MITOMYCIN C; PACLITAXEL; TEGAFUR;

ADJUVANT THERAPY; ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER SURGERY; EVALUATION; HUMAN; MEDICAL LITERATURE; PANCREAS CANCER; PANCREAS SURGERY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS;

EID: 84871194932     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318279aade     Document Type: Review

References (83)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Royal RE, Wolff RA, Crane CH. Pancreatic cancer. In: DeVita V Jr, Lawrence T, Rosenberg S, eds. Devita, Hellman, and Rosenberg's Cancer. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.
3. Tempero MA, Arnoletti JP, Behrman SW, et al. Pancreatic adenocarci-noma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012;10:703-713.
4. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreasV616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567-579.
5. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemci-tabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297: 267-277.
6. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and peri-ampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230:776-782; discussion 782-784.
7. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of che-moradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-1210.
8. Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resect-able pancreatic cancer: definitions, management, and role of preopera-tive therapy. Ann Surg Oncol. 2006;13:1035-1046.
9. Weiss AJ, Jackson L. The effect of 5-fluorouracil upon carcinomas of the gastrointestinal tract and related organs. Am J Gastroenterol. 1961; 35:138-146.
10. Kalser MH, Ellenberg SS. Pancreatic cancer. adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985; 120:899-903.
11. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer. 1987;59:2006-2010.
12. Evans DB, Wolff RA, Hess KR. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region. Ann Surg. 2000;232:727.
13. Garofalo MC, Regine WF, Tan MT. On statistical reanalysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancer. Ann Surg. 2006;244:332-333; author reply 333.
14. Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2,2¶-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs. 1994;12:29-34.
15. Regine WF, Winter KA, Abrams R, et al. Fluorouracil-based chemo-radiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. intergroup/RTOG 9704 phase III trial. Ann Surg Oncol. 2011;18: 1319-1326.
16. Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304: 1073-1081.
17. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
18. Spitz FR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduode-nectomy for adenocarcinoma of the pancreas. J Clin Oncol. 1997;15: 928-937.
19. Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pan-creaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg. 1997;226:248-257; discussion 257-260.
20. Aloia TE, Lee JE, Vauthey J, et al. Delayed recovery after pancreatico-duodenectomy: a major factor impairing the delivery of adjuvant therapy? J Am Coll Surg. 2007;204:347-355.
21. Evans DB, Byrd DR, Mansfield PF. Preoperative chemoradiotherapy for adenocarcinoma of the pancreas. rationale and technique. Am J Clin Oncol. 1991;14:359-364.
22. Jessup JM, Steele G Jr, Mayer RJ, et al. Neoadjuvant therapy for unre-sectable pancreatic adenocarcinoma. Arch Surg. 1993;128:559-564.
23. Krempien R, Muenter MW, Harms W, et al. Neoadjuvant chemoradia-tion in patients with pancreatic adenocarcinoma. HPB (Oxford). 2006; 8:22-28.
24. Allendorf JD, Lauerman M, Bill A, et al. Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocar-cinoma: feasibility, efficacy, and survival. J Gastrointest Surg. 2008; 12:91-100.
25. Wagner M, Redaelli C, Lietz M, et al. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg. 2004;91:586-594.
26. Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127:1335-1339.
27. Pisters PW, Abbruzzese JL, Janjan NA, et al. Rapid-fractionation pre-operative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol. 1998;16:3843-3850.
28. Hoffman JP, Cooper HS, Young NA, et al. Preoperative chemotherapy of chemoradiotherapy for the treatment of adenocarcinoma of the pancreas and ampulla of Vater. J Hepatobiliary Pancreat Surg. 1998;5: 251-254.
29. White RR, Hurwitz HI, Morse MA, et al. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol. 2001;8: 758-765.
30. Pisters PW, Wolff RA, Janjan NA, et al. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocar-cinoma: toxicities, histologic response rates, and event-free outcome. J Clin Oncol. 2002;20:2537-2544.
31. Calvo FA, Matute R, Garcia-Sabrido JL, et al. Neoadjuvant chemora-diation with tegafur in cancer of the pancreas: initial analysis of clinical tolerance and outcome. Am J Clin Oncol. 2004;27:343-349.
32. Talamonti MS, Small W Jr, Mulcahy MF, et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol. 2006;13:150-158.
33. Palmer DH, Stocken DD, Hewitt H, et al. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol. 2007;14:2088-2096.
34. Vento P, Mustonen H, Joensuu T, et al. Impact of preoperative chemo-radiotherapy on survival in patients with resectable pancreatic cancer. World J Gastroenterol. 2007;13:2945-2951.
35. Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3496-3502.
36. Heinrich S, Schafer M, Weber A, et al. Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg. 2008;248:1014-1022.
37. Le Scodan R, Mornex F, Partensky C, et al. Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarci-noma: the French phase II FFCD 9704-SFRO trial. Am J Clin Oncol. 2008;31:545-552.
38. Takai S, Satoi S, Yanagimoto H, et al. Neoadjuvant chemoradiation in patients with potentially resectable pancreatic cancer. Pancreas. 2008; 36:e26-e32.
39. Varadhachary GR, Wolff RA, Crane CH, et al. Preoperative gemcita-bine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008; 26:3487-3495.
40. Turrini O, Viret F, Moureau-Zabotto L, et al. Neoadjuvant 5-fluorouracilY cisplatin chemoradiation effect on survival in patients with resectable pancreatic head adenocarcinoma: a ten-year single institution experience. Oncology. 2009;76:413-419.
41. Turrini O, Ychou M, Moureau-Zabotto L, et al. Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: new neoadjuvant regimen was safe and provided an interesting pathologic response. Eur J Surg Oncol. 2010;36:987-992.
42. Papalezova KT, Tyler DS, Blazer DG 3rd, et al. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer? J Surg Oncol. 2012;106:111-118.
43. Glant JA, Waters JA, House MG, et al. Does the interval from imaging to operation affect the rate of unanticipated metastasis encountered during operation for pancreatic adenocarcinoma? Surgery. 2011;150: 607-616.
44. Kneuertz P, Cunningham S, Cameron J, et al. Palliative surgical management of patients with unresectable pancreatic adenocarcinoma: trends and lessons learned from a large, single institution experience. J Gastro-intest Surg. 2011;15:1917-1927.
45. Breslin TM, Hess KR, Harbison DB, et al. Neoadjuvant chemoradio-therapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol. 2001;8:123-132.
46. Barbier L, Turrini O, Gregoire E, et al. Pancreatic head resectable adeno-carcinoma: preoperative chemoradiation improves local control but does not affect survival. HPB (Oxford). 2011;13:64-69.
47. Artinyan A, Anaya DA, McKenzie S, et al. Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma. Cancer. 2011;117:2044-2049.
48. Mehta VK, Fisher G, Ford JA, et al. Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. J Gastrointest Surg. 2001;5:27-35.
49. Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008;206:833-846; discussion 846-848.
50. McClaine RJ, Lowy AM, Sussman JJ, et al. Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer. HPB (Oxford). 2010; 12:73-79.
51. Stokes JB, Nolan NJ, Stelow EB, et al. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol. 2011;18:619-627.
52. Patel M, Hoffe S, Malafa M, et al. Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. J Surg Oncol. 2011;104:155-161.
53. Brown KM, Siripurapu V, Davidson M, et al. Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarci-noma. Am J Surg. 2008;195:318-321.
54. Katz MH, Fleming JB, Bhosale P, et al. Response of borderline resect-able pancreatic cancer to neoadjuvant therapy is not reflected by radio-graphic indicators. Cancer. 2012.
55. DiNorcia J, Winner MD, Lee MK, et al. Neoadjuvant therapy and vascular resection during pancreaticoduodenectomy: shifting the survival curve for patients with locally advanced pancreatic cancer. J Gastro-intest Surg. In press.
56. Warshaw AL, Lillemoe KD, Fernandez-Del Castillo C. Pancreatic surgery for adenocarcinoma. Curr Opin Gastroenterol. 2012;28:488-493.
57. Coia L, Hoffman J, Scher R, et al. Preoperative chemoradiation for adeno-carcinoma of the pancreas and duodenum. Int J Radiat Oncol Biol Phys. 1994;30:161-167.
58. Kamthan AG, Morris JC, Dalton J, et al. Combined modality therapy for stage II and stage III pancreatic carcinoma. J Clin Oncol. 1997;15: 2920-2927.
59. White R, Lee C, Anscher M, et al. Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas. Ann Surg Oncol. 1999;6:38-45.
60. Bajetta E, Di Bartolomeo M, Stani SC, et al. Chemoradiotherapy as pre-operative treatment in locally advanced unresectable pancreatic cancer patients: results of a feasibility study. Int J Radiat Oncol Biol Phys. 1999;45:285-289.
61. Snady H, Bruckner H, Cooperman A, et al. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. an outcomes trial. Cancer. 2000;89:314-327.
62. Wanebo HJ, Glicksman AS, Vezeridis MP, et al. Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer. Arch Surg. 2000;135:81-87; discussion 88.
63. Crane CH, Abbruzzese JL, Evans DB, et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracilYbased chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys. 2002;52:1293-1302.
64. Moutardier V, Giovannini M, Lelong B, et al. A phase II single institutional experience with preoperative radiochemotherapy in pancreatic adenocarcinoma. Eur J Surg Oncol. 2002;28:531-539.
65. Kim HJ, Czischke K, Brennan MF, et al. Does neoadjuvant chemo-radiation downstage locally advanced pancreatic cancer? J Gastrointest Surg. 2002;6:763-769.
66. Ammori JB, Colletti LM, Zalupski MM, et al. Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J Gastrointest Surg. 2003;7:766-772.
67. Joensuu TK, Kiviluoto T, Karkkainen P, et al. Phase IYII trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2004;60: 444-452.
68. Wilkowski R, Thoma M, Schauer R, et al. Effect of chemoradiother-apy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer. World J Surg. 2004;28: 1011-1018.
69. Sa Cunha A, Rault A, Laurent C, et al. Surgical resection after radioche-motherapy in patients with unresectable adenocarcinoma of the pancreas. J Am Coll Surg. 2005;201:359-365.
70. Wilkowski R, Thoma M, Bruns C, et al. Chemoradiotherapy with gem-citabine and continuous 5-FU in patients with primary inoperable pancreatic cancer. JOP. 2006;7:349-360.
71. Lind PA, Isaksson B, Almstrom M, et al. Efficacy of preoperative radio-chemotherapy in patients with locally advanced pancreatic carcinoma. Acta Oncol. 2008;47:413-420.
72. Marti JL, Hochster HS, Hiotis SP, et al. Phase I/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancer. Ann Surg Oncol. 2008;15: 3521-3531.
73. Landry J, Catalano PJ, Staley C, et al. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol. 2010;101:587-592.
74. Leone F, Gatti M, Massucco P, et al. Induction gemcitabine and oxali-platin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience. Cancer. 2012.
75. Barugola G, Partelli S, Crippa S, et al. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadju-vant therapy. Am J Surg. 2012;203:132-139.
76. Zhao Q, Rashid A, Gong Y, et al. Pathologic complete response to neo-adjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. Ann Diagn Pathol. 2012;16:29-37.
77. Estrella JS, Rashid A, Fleming JB, et al. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. Cancer. 2012;118:268-277.
78. Sho M, Akahori T, Tanaka T, et al. Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer. J Hepatobiliary Pancreat Sci. 2012.
79. Cheng TY, Sheth K, White RR, et al. Effect of neoadjuvant chemo-radiation on operative mortality and morbidity for pancreaticoduode-nectomy. Ann Surg Oncol. 2006;13:66-74.
80. Takahashi H, Ogawa H, Ohigashi H, et al. Preoperative chemoradiation reduces the risk of pancreatic fistula after distal pancreatectomy for pancreatic adenocarcinoma. Surgery. 2011;150:547-556.
81. Gillen S, Schuster T, Meyer Zum Buschenfelde C, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7: e1000267.
82. Assifi MM, Lu X, Eibl G, et al. Neoadjuvant therapy in pancreatic adeno-carcinoma: a meta-analysis of phase II trials. Surgery. 2011;150:466-473.
83. Chua TC, Saxena A. Preoperative chemoradiation followed by surgical resection for resectable pancreatic cancer: a review of current results. Surg Oncol. 2011;20:e161-e168.